MYGN Myriad Genetics Inc.

Myriad Genetics Announces New $200 Million Credit Facility

Myriad Genetics Announces New $200 Million Credit Facility

SALT LAKE CITY, July 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has closed a five-year senior secured term loan credit facility providing up to $200 million of capital from OrbiMed, a leading global healthcare investment firm. The facility includes $125 million of funded capital with an option to borrow up to an additional $75 million until June 30, 2027. This facility matures on July 31, 2030, and bears interest at a rate based upon the one-month secured overnight financing rate (SOFR) plus 6.50% per year, subject to a SOFR floor of 2.50% per year.

“We are excited to partner with OrbiMed, a leading global healthcare investment firm. We value their insight and financial backing, which supports our ability to pursue our near-term objectives and long-term growth plan,” said Scott Leffler, chief financial officer, Myriad Genetics. “Between this credit facility and our cash and cash equivalents, we now have access to more than $200 million in capital to support the company’s growth strategy, which we will speak to in more detail on our upcoming second quarter earnings call.”

“We are pleased to partner with Myriad to support the company’s growth strategy,” said Matthew Rizzo, General Partner of OrbiMed. “We believe Myriad’s portfolio of diagnostic tests provide critical insights that enable healthcare providers to deliver better care to patients.”

The new credit facility with OrbiMed replaces Myriad's previous ABL facility. The credit facility is secured by substantially all the assets of Myriad Genetics and its subsidiaries. Additional details on the credit facility are included in the company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2025. Evercore served as exclusive financial advisor to Myriad Genetics on this transaction.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit

About OrbiMed

OrbiMed is a leading healthcare investment firm, with over $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed's team of over 130 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the term loan credit facility and how it supports the company’s ability to pursue its near-term objectives and long-term growth plan. These “forward looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Investor Contact

Matt Scalo

(801) 584-3532

Media Contact

Katie Schraml

(224) 875-4493



EN
31/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Myriad Genetics Inc.

 PRESS RELEASE

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Ben has been with Myriad for more than 13 years, joining the Company in December 2011 as assistant controller and advancing through leadership roles including vice president, corporate controller; senior vice president, accounting; and since 2022, chief financial officer, operations. Scot...

 PRESS RELEASE

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Rea...

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today released findings from its latest Cancer Risk Survey that uncover a striking contradiction in women's attitudes toward health screenings. While 80% of women report being afraid to get screened—primarily...

 PRESS RELEASE

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises ...

Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds1 of $9.5 million, revenue increased 5% year-over-year.Second quarter 2025 hereditary cancer testing revenue and volume in Oncology grew 9% and 10% year-over-year, respectively, as MyRisk with RiskScore testing volume in oncology grew 14% year-over-year. Second quarter 2025 gross margin of 71.2% increased over 160 basis points year-ov...

 PRESS RELEASE

Myriad Genetics Announces New $200 Million Credit Facility

Myriad Genetics Announces New $200 Million Credit Facility SALT LAKE CITY, July 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has closed a five-year senior secured term loan credit facility providing up to $200 million of capital from OrbiMed, a leading global healthcare investment firm. The facility includes $125 million of funded capital with an option to borrow up to an additional $75 million until June 30, 2027. This facility matures on July 31, 2030, and bears interest at a rate based upon the one-mo...

 PRESS RELEASE

Myriad Genetics to Release Second Quarter 2025 Financial Results on Au...

Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025 SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter 2025. A live webcast of the conference call can be ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch